PRAX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWPraxis Precision Medicines Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nov 9, 2026

8-K

Praxis Precision Medicines Reports Q2 2026 Financial Results and Provides Corporate Update

Aug 6, 2026

8-K

Praxis Precision Medicines Enters Research Collaboration with Remagine Labs for Transdermal Ulixacaltamide

Jul 7, 2026

8-K

Praxis Precision Medicines, Inc. Announces Change of Independent Registered Public Accounting Firm

Jul 2, 2026

8-K

FDA Extends Review Period for Praxis Precision Medicines’ Relutrigine NDA

Jun 29, 2026

8-K

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen (PRAX-222)

Jun 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

FIXED PRICE OFFERING - COMMON STOCK | Offering amount: $575,120,000 | Shares: 2,212,000 | Price: $260.000 | Bank: Piper Sandler

Jan 7, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Piper Sandler

Jan 6, 2026

424B5

FIXED PRICE OFFERING - COMMON STOCK | Offering amount: $525,000,118 | Shares: 3,343,950 | Price: $157.000 | Bank: TD Cowen

Oct 17, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: TD Cowen, Piper Sandler, Guggenheim Securities, Truist Securities

Oct 16, 2025

424B5

September 2025 ATM | Offering amount: $250,000,000

Sep 5, 2025

424B5

SHELF OFFERING | Shares amount: 3,318,585 | Share price: $56.50 | Warrants amount: 221,238 | Offering amount: $199,999,977.38

Mar 29, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 28, 2025

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Dec 23, 2024

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jun 10, 2024

S-3

SHELF | ATM | Offering amount: $750,000,000.00 EFFECTIVE

Mar 5, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G/A

ORBIS INVESTMENT MANAGEMENT LTD (Filed by)

Aug 14, 2026

Souza Marcio (Reporting)

Jul 8, 2026

DeSimone Jill (Reporting)

Jun 26, 2026

144

Form 144 - Report of proposed sale of securities

Jun 24, 2026

Arbuckle Stuart A (Reporting)

Jun 12, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 13, 2024

CORRESP

Form CORRESP - Correspondence

Mar 8, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 8, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 10, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

May 19, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

May 14, 2021

Praxis Precision Medicines, Inc. PRAX · SEC Filings